sprite-preloader
Anzeige
Mehr »
Montag, 23.10.2017 Börsentäglich über 12.000 News von 567 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1W5NZ ISIN: US3504651007 Ticker-Symbol: 8FM 
Aktie:
Branche
Biotechnologie
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
FOUNDATION MEDICINE INC Chart 1 Jahr
1-Woche-Intraday-Chart
FOUNDATION MEDICINE INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
34,539
35,602
11:59
12.08.2017 | 05:09
(13 Leser)
Schrift ändern:
(1 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / August 11, 2017 / Pomerantz LLP is investigating claims on behalf of investors of Foundation Medicine, Inc. ('Foundation' or the 'Company') (NASDAQ: FMI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, Ext. 9980.

The investigation concerns whether Foundation and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On July 29, 2015, Foundation issued a press release announcing its second quarter 2015 financial results and downgrading its financial guidance. The Company stated, in part, that Foundation's 'clinical volume growth was affected by slower than anticipated progress toward obtaining a local coverage determination from [its] regional Medicare Administrative Contractor,' and that '[a]s a result, [the Company was] adjusting guidance for clinical volume and annual revenues.' The Company reduced its 2015 clinical test guidance to 'between 35,000 and 38,000 clinical tests,' down significantly from 'between 43,000 and 47,000 clinical tests in 2015,' and its 2015 revenue guidance to 'the range of $85 to $95 million,' also down significantly from 'the range of $105 - $115 million.' On a conference call with investors that same day, Foundation's CEO stated that the Company was 'no longer assuming any Medicare payment for the rest of 2015.' On this news, Foundation's share price fell $7.00, or 23.89%, to close at $22.30.

Then, on November 3, 2015, Foundation disclosed a further revision to the number of clinical tests it expected to report for 2015, updating its range to 32,000 to 33,000, a material reduction from the range announced on July 29, 2015. On this news, Foundation's share price fell $6.62, or 27.66%, to close at $17.31 on November 4, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP


© 2017 ACCESSWIRE